Melanoma in 2017

Moving treatments earlier to move further forwards

In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Luke, J. J. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).

    CAS  Article  Google Scholar 

  3. 3

    Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7

    Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9

    Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006 [abstract]. Pigm. Cell Melanoma Res. 30, 76–156 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

M.A.D. acknowledges funding support from the US National Cancer Institute (grants 1R01CA187076-02, 1U54CA224070-01, and 2T32CA009666-21), The Cancer Prevention and Research Institute of Texas (RP160183), the Melanoma Research Alliance, and the Melanoma Research Foundation. Both M.A.D and K.T.F. acknowledge funding support from the Dr Miriam and Sheldon G. Adelson Medical Research Foundation.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Keith T. Flaherty.

Ethics declarations

Competing interests

M.A.D. has served on advisory boards for BMS, Novartis, Roche/Genentech, Sanofi-Aventis, and Vaccinex, and has been the Principal Investigator of studies funded by grants to his institution from AstraZeneca, BMS, Oncothyreon, Roche/Genentech, and Sanofi-Aventis. K.T.F. has served on advisory boards for BMS, Merck, Novartis, and Roche/Genentech, and has received grant support from Novartis.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Davies, M., Flaherty, K. Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 15, 75–76 (2018). https://doi.org/10.1038/nrclinonc.2017.183

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing